On December 31, 2024, the Shuanghai brand Danshen tablets (180 tablets) produced by Shanghai Huanghai Pharmaceutical, a subsidiary of Shanghai Baiyang Pharmaceutical, passed strict review and fierce competition, and won the bid for centralized procurement of the National traditional Chinese patent medicines and simple preparations Purchasing Alliance led by Hubei Province, which means that more patients can enjoy this high-quality medical resource at a more affordable price, which is a solid step on the road of fulfilling our social responsibility. 

The Shuanghai brand Danshen tablets produced by Shanghai Huanghai Pharmaceutical adopt advanced production technology and undergo strict quality control processes to ensure that each pill can achieve good therapeutic effects, providing patients with safe and reliable medication choices. At the same time, this product stands out among similar products due to its unique characteristics of rapid onset, minimal side effects, and wide applicability. It is effective in promoting blood circulation and removing blood stasis, and significantly improving the quality of life of patients with chest pain, fixed pain areas, dark purple tongue, and angina pectoris caused by stagnant blood stasis. This winning bid is not only a high recognition of the excellent efficacy and safety of Shuanghai brand Danshen tablets, but also the best proof of our commitment to innovation driven development strategy and continuous improvement of product quality.

Looking ahead to the future, Shanghai Huanghai Pharmaceutical will take this opportunity to continue increasing research and development investment, deepening industry university research cooperation, and continuously launching more innovative drugs to meet diverse clinical needs. At the same time, we will actively respond to national policies, optimize supply chain management, ensure stable drug supply, and contribute to improving the national health level.